AbbVie Inc. (NYSE:ABBV) was downgraded by equities research analysts at UBS AG from a “buy” rating to a “neutral” rating in a report released on Monday, 247wallst.com reports. They currently have a $92.00 price objective on the stock, up from their prior price objective of $79.00. UBS AG’s price objective would suggest a potential upside of 5.17% from the stock’s previous close.

ABBV has been the subject of several other reports. Vetr upgraded AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price objective for the company in a research note on Wednesday, July 26th. Deutsche Bank AG reiterated a “hold” rating and set a $66.00 price objective (up from $65.00) on shares of AbbVie in a research note on Monday, July 17th. BidaskClub lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Jefferies Group LLC reiterated a “buy” rating and set a $94.00 price objective (up from $92.00) on shares of AbbVie in a research note on Monday, July 17th. Finally, Zacks Investment Research upgraded AbbVie from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $83.02.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. During the same period in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “AbbVie Inc. (ABBV) Lowered to Neutral at UBS AG” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/25/ubs-ag-downgrades-abbvie-inc-abbv-to-neutral.html.

In other news, Director Edward J. Rapp acquired 4,000 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was purchased at an average cost of $70.45 per share, for a total transaction of $281,800.00. Following the completion of the transaction, the director now directly owns 15,498 shares in the company, valued at $1,091,834.10. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the completion of the sale, the senior vice president now owns 93,099 shares of the company’s stock, valued at $7,915,276.98. The disclosure for this sale can be found here. Over the last quarter, insiders sold 373,191 shares of company stock valued at $26,598,305. Corporate insiders own 0.23% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Capital Research Global Investors increased its position in AbbVie by 1.2% in the second quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock worth $12,926,708,000 after purchasing an additional 2,130,919 shares during the period. Vanguard Group Inc. increased its position in AbbVie by 3.3% in the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock worth $8,405,409,000 after purchasing an additional 3,706,941 shares during the period. BlackRock Inc. increased its position in AbbVie by 2.0% in the second quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock worth $6,821,375,000 after purchasing an additional 1,864,418 shares during the period. State Street Corp increased its position in AbbVie by 2.4% in the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after purchasing an additional 1,696,042 shares during the period. Finally, Orbis Allan Gray Ltd increased its position in AbbVie by 35.7% in the second quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock worth $921,233,000 after purchasing an additional 3,340,038 shares during the period. Hedge funds and other institutional investors own 68.25% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.